



Gamma Delta T Cells and Organ Transplantation: A Review of Recent Studies

Rumeysa Yegin, Aeisha Ahmed, Gulam Hekimoglu

¹Hamidiye International School of Medicine, University of Health Sciences, Senior Medical Student, İstanbul, Türkiye

²Hamidiye International School of Medicine, University of Health Sciences, Department of Histology and Embryology, İstanbul, Türkiye

Copyright@Author(s) - Available online at www.dergipark.org.tr/tr/pub/medr

Content of this journal is licensed under a Creative Commons Attribution-NonCommercial-NonDerivatives 4.0 International License.



Abstract

Gamma delta ($\gamma\delta$) T cells have gained a lot of attention in the field of cancer immunotherapy due to their unique innate and adaptive immune properties. However, until recently, their potential significance in organ transplantation went unnoticed. This review highlights the effector roles and potential advantages of $\gamma\delta$ T cells in organ transplantation by examining recent studies examining the connection between T cells and organ transplantation. Recent studies have shown that high $\gamma\delta$ T-cell immune reconstitution following organ transplantation is associated with a significantly greater overall survival rate and a lower incidence of acute graft-versus-host disease (GVHD), despite prior studies' contradictory findings. These results suggest that $\gamma\delta$ T cells might be a useful addition to the current transplantation procedures. The effector activities of $\gamma\delta$ T cells and their putative modes of action following organ transplantation will be covered in this review. We also provide a summary of the most recent research on the connection between $\gamma\delta$ T cells and organ transplant outcomes, such as acute GVHD and graft survival. Finally, we point out the areas that still need to be studied in order to fully comprehend how $\gamma\delta$ T cells function after organ donation.

Keywords: Phase angle, diabetes mellitus, fasting glucose, hemoglobin A1c

INTRODUCTION

A distinct subpopulation of lymphocytes known as gamma delta ($\gamma\delta$) T cells possess both innate and adaptive immunological features. In contrast to the alpha-beta ($\alpha\beta$) TCR expressed by typical T cells, they express a T-cell receptor (TCR) made up of gamma and delta chains (1). It is well recognized that $\gamma\delta$ T cells are essential for a number of immunological responses, including tumor surveillance, pathogen removal, and tissue homeostasis (2). $\gamma\delta$ T cells may play a part in organ transplantation, according to recent investigations (3).

The most successful course of action for end-stage organ failure is organ transplantation. Immune rejection, in which the recipient's immune system perceives

the transplanted organ as foreign and develops an immunological response against it, limits the success of organ transplantation. Drugs that suppress the immune system are used to prevent immunological rejection, but long-term usage is linked to a number of problems, including infections and cancers (4). To enhance the results of organ transplantation, it is, therefore, necessary to investigate new immunotherapy options.

$\gamma\delta$ T cells may have a function in organ transplantation, according to current studies. The effects of $\gamma\delta$ T cells on organ transplantation have been studied in the past, but the findings have been mixed. While some research indicated that $\gamma\delta$ T cells had a positive effect, other investigations found no effect or possibly a negative effect (5,6). To better appreciate the potential advantages

CITATION

Yegin R, Ahmed A, Hekimoglu G. Gamma Delta T Cells and Organ Transplantation: A Review of Recent Studies. *Med Records*. 2023;5(3):659-63. DOI:1037990/medr.1293786

Received: 07.05.2023 **Accepted:** 25.06.2023 **Published:** 12.07.2023

Corresponding Author: Gulam Hekimoglu, Hamidiye International School of Medicine, University of Health Sciences, Department of Histology and Embryology, İstanbul, Türkiye

E-mail: gulam.hekimoglu@sbu.edu.tr

and disadvantages of $\gamma\delta$ T cells and organ donation, it is necessary to analyze the available evidence.

In this essay, we examine the most recent research on the function of $\gamma\delta$ T cells after organ donation. We talk about the effector capabilities of $\gamma\delta$ T cells and possible organ transplantation strategies they might employ. We also provide a summary of the most recent research on the association between $\gamma\delta$ T cells and organ transplant outcomes, such as acute GVHD and graft survival. Finally, we point out the areas that still need to be studied to fully comprehend how $\gamma\delta$ T cells function after organ donation.

$\gamma\delta$ T cells

T lymphocytes have a special subgroup known as $\gamma\delta$ T cells, which contain TCR γ and δ chains (7). $\gamma\delta$ T cells can detect antigens in a TCR-dependent or -independent way, in contrast to traditional $\alpha\beta$ T cells (8). The liver, gut, and epithelial tissues are only a few of the tissues where they can be found (9).

Based on how their TCRs are expressed, V γ 9V δ 2 T cells and non-V γ 9V δ 2 T cells are the two main categories of $\gamma\delta$ T cells (10). The most prevalent type of $\gamma\delta$ T-cell subset in peripheral blood is V γ 9V δ 2 T cells, which accounts for up to 5% of circulating T cells in healthy people (11). They detect phosphorylated non-peptidic antigens produced by different bacteria and tumor cells, such as isopentenyl pyrophosphate (IPP) (12). Although less well understood, non-V γ 9V δ 2 T cells are capable of recognizing a wide range of antigens, including self-antigens and stress-induced molecules (13).

Recent research has also raised the possibility of tissue-resident $\gamma\delta$ T cells, which are essential for immune surveillance and tissue homeostasis (14). These tissue-resident $\gamma\delta$ T cells differ from the circulating $\gamma\delta$ T cells in that they have a high level of tissue selectivity (15).

$\gamma\delta$ T cells and organ transplantation

Early studies on the organ transplant effect of $\gamma\delta$ T cells: the role of $\gamma\delta$ T cells in organ transplantation has been investigated since the 1990s. Early studies suggested that $\gamma\delta$ T cells might contribute to graft rejection due to their potent cytotoxic activity and pro-inflammatory cytokine production (16). However, other studies reported conflicting results, with some indicating that $\gamma\delta$ T cells might have a protective role in graft survival (17).

Recent studies on $\gamma\delta$ T cells immune reconstitution after organ transplantation: the favorable impact of $\gamma\delta$ T cells in organ transplantation has been demonstrated by more recent investigations. Studies have confirmed that patients, who received bone marrow transplantation and had high levels of $\gamma\delta$ T cells experienced considerably lower incidences of GVHD and greater overall survival rates (18). Similar findings were made regarding kidney transplant recipients, where it was discovered that higher levels of circulating $\gamma\delta$ T cells were linked to improved graft function and a lower risk of acute rejection (19).

$\gamma\delta$ T cells have also been demonstrated to be important

in the immune system's recovery following organ transplantation. The recovery of $\gamma\delta$ T cells in peripheral blood was linked to a lower risk of post-transplant infections in a study of liver transplant recipients (20). Similarly, early $\gamma\delta$ T cells recovery after heart transplantation was linked to a lower risk of infection and better graft survival (21).

These studies collectively imply that $\gamma\delta$ T cells might be useful in organ transplantation. To clarify the underlying mechanisms and decide when and how much to provide $\gamma\delta$ T cells-based treatments, more investigation is required.

Effector mechanisms, subtypes in several organ transplantations

A diverse group of T cells known as $\gamma\delta$ T cells possess both innate and adaptive immunological capabilities. They are capable of identifying and reacting to a variety of antigens, including self-antigens produced by stress and non-peptidic antigens delivered by non-classical major histocompatibility complex (MHC) molecules (22, 23).

The effector mechanisms and $\gamma\delta$ T cell subtypes in the setting of organ transplantation have been the subject of numerous research. According to one study, V δ 1 T cells, a subtype of $\gamma\delta$ T cells, were protective against acute rejection and were selectively increased in the peripheral blood of kidney transplant recipients (23). The most common T-cell subset in human blood, V δ 2 T cells, was discovered to play a cytotoxic role in the rejection of liver transplants in another investigation (24).

Furthermore, diverse subsets of $\gamma\delta$ T cells have been discovered to have various effector capabilities. For instance, some $\gamma\delta$ T-cell subsets create anti-inflammatory cytokines like interleukin (IL)-10, while others produce pro-inflammatory cytokines like interferon-gamma (IFN- γ) and tumor necrosis factor-alpha (TNF- α) (25). Additionally, it has been discovered that some T-cell subsets possess regulatory abilities, such as the capacity to inhibit T-cell growth and control dendritic cell activity (26).

Liver transplantation is a life-saving treatment for diverse etiologies of end-stage liver disease. Immunosuppression (IS) therapy must be administered for the remainder of a patient's life to maintain the function of an allograft liver. Patients on lifelong IS therapy had a higher mortality rate than the normal population because of infections, cancers, cardiovascular problems, and incomplete liver function preservation (27). $\gamma\delta$ T cells after liver transplantation have both good and bad consequences, according to studies. Patients with liver transplant rejection have been found to have the presence of $\gamma\delta$ 2+ T cells, and it is considered that these $\gamma\delta$ 2 T cells may be the cause of allograft rejection. As one of T cells' beneficial effects, they lower the likelihood of GVHD, which worsens with organ damage as a result of an intense immune response mediated by healthy T lymphocytes. Intolerant liver recipients show an increase in $\gamma\delta$ 1+ T cell infiltration. It has been observed that it causes the release of interleukin (IL)-4 and IL-10, which results in the protection of allografts, particularly in the liver (28) (Figure 1).




Figure 1: $\gamma\delta$ T cells following liver transplantation have both good and bad consequences. Rejection of liver allografts has been linked to the presence of $\gamma\delta 2+$ T cells. However, IL-4 and IL-10 are secreted when a $\gamma\delta 1+$ T cells is activated, protecting the liver allograft. IL-17 from $\gamma\delta$ T cells contributes to acute and chronic allograft dysfunction in lung transplants. The acute rejection of lung allografts and the early phases of renal allograft rejection is accompanied by an increase in TNF- α and IFN- γ production. In hematopoietic stem cell transplantation, acute GVHD is more common and is correlated with $\gamma\delta$ T cells

Renal transplantation is chosen in individuals with end-stage renal failure as a therapeutic option. Transplantation necessitates long-term chronic immunosuppression to prevent acute rejection and increase graft survival. Studies have demonstrated that by releasing pro-inflammatory cytokines such as IFN- γ and TNF- α , $\gamma\delta$ T cells can influence the early stages of renal allograft rejection (29). Additionally, during acute rejection episodes, it has been observed that $\gamma\delta$ T cells infiltrate the renal graft, indicating their possible role in the etiology of renal allograft rejection (30).

On the other side, it has also been demonstrated that $\gamma\delta$ T cells contribute to the development of tolerance to renal allografts. For instance, it has been discovered that $\gamma\delta$ T cells can secrete immunoregulatory cytokines like IL-10, which can inhibit the activation of conventional T cells and encourage tolerance (31). Furthermore, some research has indicated that, under specific conditions, $\gamma\delta$ T cells might contribute to the induction of transplant tolerance. A specific $\gamma\delta$ T cell agonist was reported to be able to prolong the survival of cardiac allografts in mice in one investigation, indicating the potential therapeutic role of $\gamma\delta$ T cells in fostering transplant tolerance (32).

Overall, $\gamma\delta$ T cells have a complex and context-specific role in renal transplantation. Although they have the potential to cause acute rejection and inflammation, they can also foster tolerance and long-term graft survival (Figure 1).

Allogeneic hematopoietic stem cell transplantation is a therapeutic approach that is increasingly being employed with individuals who have hematological malignancies. $\gamma\delta$ T cells are a distinct subset of lymphocytes that play a key role in innate immunity against a range of illnesses and have strong anticancer activity (33). They quickly regenerate following bone marrow transplantation, in contrast to $\alpha\beta$ T cells, which take longer to mend and lead

to an immunological deficit in the months immediately following transplantation. It is highly debatable whether or not $\gamma\delta$ T cells play a role in GVHD prevention or promotion, which is one of the most frequent causes of posttransplant mortality after bone marrow transplantation. This is because distinct subsets of $\gamma\delta$ T cells may have conflicting effects. While some research suggests that having more $\gamma\delta$ T cells is linked to an increased frequency of acute GVHD, other research contends that there is no link between having more $\gamma\delta$ T cells and GVHD or that having fewer cells is linked to a greater incidence of condition (34). As a result of their involvement in leukemia and infection control, $\gamma\delta$ T cells are also expected to contribute significantly to the efficacy and safety of bone marrow transplantation, increasing patient survival (35) (Figure 1).

Pulmonary transplantation is a treatment that can treat terminal lung disease and save lives. With a median life of only 6.5 years, pulmonary transplant recipients had a worse long-term survival rate than those of other solid organ transplant recipients. Meanwhile, research has demonstrated that interleukin (IL)-17+ $\gamma\delta$ T cells during mouse pulmonary transplantation, after 21 days of transplantation, it has been noted that it makes up a sizable fraction of the infiltrating immune cells, and in small animal lung transplant models, the generation of IL-17 by $\gamma\delta$ T cells also plays a role in acute and chronic allograft failure (36).

In accordance with findings from additional research, $\gamma\delta$ T cells have a role in both the early and late stages of pulmonary allograft rejection. Additionally, their presence in lung tissue is linked to an increase in inflammation and tissue damage. According to one study, acute pulmonary allograft rejection resulted in a large increase in $\gamma\delta$ T cells, and their activation was linked to an increase in the production of pro-inflammatory cytokines like TNF- α and IFN- γ (37).

$\gamma\delta$ T cells have been linked to promoting tolerance to pulmonary allografts in addition to their pro-inflammatory function. These cells can release immunoregulatory cytokines including IL-10 and transforming growth factor beta (TGF- β), and studies have linked their presence to lower rates of acute rejection and better long-term graft survival (38) (Figure 1).

The effector mechanisms and $\gamma\delta$ T cell subtypes involved in organ transplantation are intricate and varied overall. To clarify the functional functions of various $\gamma\delta$ T-cell subsets in certain transplant situations and to identify the most effective methods for influencing $\gamma\delta$ T-cell responses for therapeutic goals, more study is required.

CONCLUSION

In conclusion, $\gamma\delta$ T cells represent a diverse population of lymphocytes with innate and adaptive immunological characteristics. They play a complex and multidimensional function in organ transplantation, with early investigations yielding contradictory findings. However, recent research

has indicated that strong $\gamma\delta$ T-cell immune reconstitution following organ transplantation has an advantageous outcome. High $\gamma\delta$ T-cell counts had a considerably greater survival rate and lesser acute GVHD cases. It is still unclear how effector mechanisms and different types of $\gamma\delta$ T cells function after organ transplantation; some subsets play protective functions while others play cytotoxic roles during rejection. To completely comprehend the functional functions of various $\gamma\delta$ T-cell subsets in certain transplant contexts and to identify the most effective methods for influencing $\gamma\delta$ T-cell responses for therapeutic reasons in organ transplantation, more study is required. Overall, immunomodulatory medicines in organ transplantation may find success with targeting $\gamma\delta$ T cells.

Financial disclosures: The authors declared that this study has received no financial support.

Conflict of Interest: The authors have no conflicts of interest to declare.

Acknowledgment: The figure was "created with BioRender.com." The authors thank BioRender for their contributions.

REFERENCES

- Wencker M, Turchinovich G, Di Marco Barros R, et al. Innate-like T cells straddle innate and adaptive immunity by altering antigen-receptor responsiveness. *Nat Immunol.* 2014;15:80-7.
- Vantourout P, Hayday A. Six-of-the-best: unique contributions of $\gamma\delta$ T cells to immunology. *Nat Rev Immunol.* 2013;13:88-100.
- Minculescu L, Sengeløv H. The role of gamma delta T cells in haematopoietic stem cell transplantation. *Scand J Immunol.* 2015;81:459-68.
- Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. *Am J Transplant.* 2004;4:905-13.
- Theirez A, Sabourin C, Gertner-Dardenne J, et al. Self/non-self discrimination by human $\gamma\delta$ T cells: simple solutions for a complex issue? *Immunol Rev.* 2007;215:123-35.
- Pauza CD, Liou ML, Lahusen T, et al. Gamma delta T cell therapy for cancer: it is good to be local. *Front Immunol.* 2018;9:1305.
- Wencker M, Turchinovich G, Di Marco Barros R, et al. Innate-like T cells straddle innate and adaptive immunity by altering antigen-receptor responsiveness. *Nat Immunol.* 2014;15:80-7.
- Carding SR, Egan PJ. Gammadelta T cells: functional plasticity and heterogeneity. *Nat Rev Immunol.* 2002;2:336-45.
- Witherden DA, Rieder SE, Boismenu R, et al. A role for epithelial $\gamma\delta$ T cells in tissue repair. *Springer Semin Immunopathol.* 2000;22:265–81.
- Silva-Santos B, Serre K, Norell H. $\gamma\delta$ T cells in cancer. *Nat Rev Immunol.* 2015;15:683–91.
- Scotet E, Martinez LO, Grant E, et al. Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. *Immunity.* 2005;22:71-80.
- Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human $\gamma\delta$ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. *Cancer Res.* 2007; 67:74507.
- Brandes M, Willmann K, Moser B. Professional antigen-presentation function by human gamma-delta T Cells. *Science.* 2005;309:264-8.
- Sheridan BS, Lefrançois L. Regional and mucosal memory T cells. *Nat Immunol.* 2011;12:485-91.
- Cai Y, Xue F, Fleming C, et al. Differential developmental requirement and peripheral regulation for dermal V γ 4 and V γ 6T17 cells in health and inflammation. *Nature communications.* 2014;5:3986.
- Yu X, Liu Z, Wang Y, et al. Characteristics of V δ 1+ and V δ 2+ $\gamma\delta$ T cell subsets in acute liver allograft rejection. *Transpl Immunol.* 2013;29:118-22.
- McCallion O, Hester J, Issa F. Deciphering the contribution of $\gamma\delta$ T cells to outcomes in transplantation. *Transplantation.* 2018;102:1983-93.
- Minculescu L, Marquart HV, Ryder LP, et al. Improved overall survival, relapse-free-survival, and less graft-vs.-host-disease in patients with high immune reconstitution of TCR gamma delta cells 2 months after allogeneic stem cell transplantation. *Front Immunol.* 2019;10:1997.
- Sur S, Ravoor A, San Juan SP, et al. Flow cytometric pattern of gamma delta TCR expression identifies outcomes in kidney transplantation. *Transplantation.* 2022;106: S312.
- Martínez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. *Am J Transplant.* 2007;7:309-19.
- Xia Q, Duan L, Shi L, et al. High-mobility group box 1 accelerates early acute allograft rejection via enhancing IL-17+ $\gamma\delta$ T-cell response. *Transpl Int.* 2014;27:399-407.
- Born WK, Reardon CL, O'Brien RL. The function of $\gamma\delta$ T cells in innate immunity. *Curr Opin Immunol.* 2006;18:31-8.
- Puig-Pey I, Bohne F, Benítez C, et al. Characterization of $\gamma\delta$ T cell subsets in organ transplantation. *Transpl Int.* 2010;23:1045-55.
- Mao Y, Yin S, Zhang J, et al. A new effect of IL-4 on human $\gamma\delta$ T cells: promoting regulatory V δ 1 T cells via IL-10 production and inhibiting function of V δ 2 T cells. *Cell Mol Immunol.* 2016;13:217–28.
- Caccamo N, Battistini L, Bonneville M, et al. CXCR5 identifies a subset of V γ 9V δ 2 T cells which secrete IL-4 and IL-10 and help B cells for antibody production. *J Immunol.* 2006;177:5290-5.
- Peterfalvi A, Gomori E, Magyarlaci T, et al. Invariant Valpha7.2-Jalpha33 TCR is expressed in human kidney and brain tumors indicating infiltration by mucosal-associated invariant T (MAIT) cells. *Int Immunol.* 2008;20:1517-25.
- Cvetkovski F, Hexham JM, Berglund E. Strategies for Liver Transplantation Tolerance. *International journal of molecular sciences.* 2021;24:2253.
- Sullivan LC, Shaw EM, Stankovic S, et al. The complex

- existence of $\gamma\delta$ T cells following transplantation: the good, the bad and the simply confusing. *Clinical & translational immunology*. 2019;8,e1078.
29. Lee S, Affandi JS, Irish AB, et al. Cytomegalovirus infection alters phenotypes of different $\gamma\delta$ T-cell subsets in renal transplant recipients with long-term stable graft function. *J Med Virol*. 2017;89:1442-52.
 30. Girardi M. Immunosurveillance and immunoregulation by $\gamma\delta$ T cells. *J Invest Dermatol*. 2006;126:25-31.
 31. Zhou J, Appleton SE, Stadnyk, et al. CD8+ gammadelta T regulatory cells mediate kidney allograft prolongation after oral exposure to alloantigen. *Transpl Int*. 2008;21-679-87.
 32. Hohegger K, Schätz T, Eller P, et al. Role of α/β and γ/δ T cells in renal ischemia-reperfusion injury. *Am J Physiol Renal Physiol*. 2007;293: F741-7.
 33. Bian Z, Xu LP, Fu Q, et al. Homeostatic $\gamma\delta$ T cell contents are preserved by granulocyte colony-stimulating factor priming and correlate with the early recovery of $\gamma\delta$ T cell subsets after haploidentical hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2018;24:252-9.
 34. de Witte MA, Sarhan D, Davis Z, et al. Early reconstitution of NK and $\gamma\delta$ T cells and its implication for the design of post-transplant immunotherapy. *Biol Blood Marrow Transplant*. 2018;24:1152-62.
 35. Saura-Esteller J, de Jong M, King LA, et al. Gamma delta T-Cell based cancer immunotherapy: past-present-future. *Front Immunol*. 2022;13:915837.
 36. Giri S, Lal G. Differentiation and functional plasticity of gamma-delta ($\gamma\delta$) T cells under homeostatic and disease conditions. *Mol Immunol*. 2021;136:138-49.
 37. Lahn M. The role of $\gamma\delta$ T cells in the airways. *J Mol Med*. 2000;78:409-25.
 38. Sullivan L, Shaw E, Snell G, et al. A longitudinal study of $\gamma\delta$ T cell subsets post lung transplant: potential players in CMV immunity. *The Journal of Heart and Lung Transplantation*. 2019;38:S253.